FDA announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.
FDA is requesting nominations by Dec. 14 for voting members to serve on the Tobacco Products Scientific Advisory Committee.
FDA launches Rare Disease Framework Initiative for drug development
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair.
FDA expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin to include patients with BCG-unresponsive NMIBC with papillary-only tumors.
As the oncology community waits with bated breath for a possible FDA approval of GRAIL’s Galleri test, NCI Director Anthony Letai has a lot to say about multi-cancer detection tests—particularly Galleri.
FDA approved Tuksya (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive breast cancer following induction treatment. The approval expands the use of Tuksya to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that may help further delay disease progression.
Nearly two years after FDA issued a final rule requiring radiologists to tell women whether their breasts are “dense” or “not dense” after a mammogram, the notification has become nearly universal.
